About the Journal

Aims and scope
Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair.

Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.

Frequency
12 issues a year

Journal Metrics
Article metrics such as number of downloads, citations and online attention are available from each article page, and provide an overview of the attention received by a paper.

The 2018 peer review performance metrics for Cancer Gene Therapy are shown below:

  • Average time to decision without external review - 26 days
  • Average time to decision following external review - 40 days
  • Over 61,800 recipients in receipt of the monthly electronic table of contents alert.
  • Over 200,000 views to journal articles per year.

The 2018 journal metrics* for Cancer Gene Therapy are as follows:

  • 2-year Impact Factor: 4.044
  • Journal Rank: 27/160 Biotechnology & Applied Micobiology | 69/222 Oncology | 40/171 Genetics & Heredity | 31/133 Medicine, Research & Experimental
  • 5-year Impact Factor: 3.008
  • Immediacy index: 1.125
  • Eigenfactor® score: 0.00361
  • Article Influence Score: 0.657

*2017 Journal Citation Reports® Science Edition (Clarivate Analytics, 2018)

Abstracted/indexed in

BIOSIS
Google Scholar
Medline
OCLC
Science Citation Index
Science Citation Index Expanded
Current Contents/Clinical Medicine
Current Contents/Life Sciences
Scopus
Summon by ProQuest
EBSCO Discovery Service
EBSCO Academic Search
EMBASE

ISSN and eISSN

The international standard serial number (ISSN) for Cancer Gene Therapy is 0929-1903, and the electronic international standard serial number (eISSN) is 1476-5500.

Newsfeeds

Cancer Gene Therapy now provides its latest table of contents as an RSS web  feed. This allows users with an RSS reader to receive automatic updates whenever new content is added to these pages.

Receive Cancer Gene Therapy's current issue table of contents.

Receive Cancer Gene Therapy's AOP table of contents.